Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of COVID-19 Booster-Dose Vaccine for Re-infection Precaution and Dynamics of Specific Serum Antibodies in the Management of Lung Cancer Patients With Systemic Anti-cancer Treatment

NCT06168032 is registered in ClinicalTrials.gov with Peking Union Medical College Hospital as lead sponsor.

NCT NCT06168032
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06168032 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of COVID-19 Booster-Dose Vaccine for Re-infection Precaution and Dynamics of Specific Serum Antibodies in the Management of Lung Cancer Patients With Systemic Anti-cancer Treatment
Lead sponsor
Peking Union Medical College Hospital
Phase
Not applicable
Overall status
Recruiting
Start date
December 8, 2023
Completion date
December 8, 2026
Enrollment
1,224 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

antibody, chemotherapy, covid-19 recurrent, immune checkpoint inhibitor, lung cancer, vaccination